Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-27

Clinical Trial Update: A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating semaglutide in early Alzheimer's disease has completed. No efficacy results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Early Alzheimer´s Disease | Phase 3 | Status: COMPLETED